SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 0.72 |
| Enterprise Value ($M) | 7.19 |
| Book Value ($M) | 0.37 |
| Book Value / Share | 0.05 |
| Price / Book | 1.95 |
| NCAV ($M) | -1.24 |
| NCAV / Share | -0.16 |
| Price / NCAV | -0.58 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.05 |
| Return on Assets (ROA) | -0.04 |
| Return on Equity (ROE) | -5.81 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.51 |
| Current Ratio | 0.76 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 3.56 |
| Assets | 5.17 |
| Liabilities | 4.80 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 9.09 |
| Operating Income | -0.07 |
| Net Income | -0.21 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.01 |
| Cash from Investing | -0.17 |
| Cash from Financing | -0.20 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Similar Companies | |
|---|---|
| IPHYF – Innate Pharma S.A. | IPIX – Innovation Pharmaceuticals Inc. |
| IPSEF – Ipsen S.A. | IVBT – Innovation1 Biotech Inc. |
| IVEVF – Inventiva S.A. |
Financial data and stock pages provided by
Fintel.io